Improved insulin sensitivity (↑ glucose uptake) in T2D/metabolic syndrome recipients following healthy FMT. Potential to reduce hepatic steatosis and inflammation in NAFLD by decreasing endotoxemia and proinflammatory signals. Some patients showed reductions in ALT and liver inflammation after FMT, though effects were variable. Long-term benefits and safety (e.g., durability of microbiome changes) are still under study. The gene discussed is INS; the disease is metabolic syndrome.